<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Morphology</journal-id><journal-title-group><journal-title xml:lang="en">Morphology</journal-title><trans-title-group xml:lang="ru"><trans-title>Морфология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1026-3543</issn><issn publication-format="electronic">2949-2556</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">641577</article-id><article-id pub-id-type="doi">10.17816/morph.641577</article-id><article-id pub-id-type="edn">WKNIYP</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Somatometric and Bioimpedance Parameters in the Assessment of Physical Development in Patients with Esophageal Cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Соматометрические и биоимпедансометрические показатели в оценке физического развития пациентов с раком пищевода</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Somatometric and Bioimpedance Parameters in the Assessment of Physical Development in Patients with Esophageal Cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-0749-0778</contrib-id><contrib-id contrib-id-type="spin">6223-7575</contrib-id><name-alternatives><name xml:lang="en"><surname>Startsev</surname><given-names>Sergey S.</given-names></name><name xml:lang="ru"><surname>Старцев</surname><given-names>Сергей Станиславович</given-names></name><name xml:lang="zh"><surname>Startsev</surname><given-names>Sergey S.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sakhstar2010@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5297-5980</contrib-id><contrib-id contrib-id-type="spin">8525-7253</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbunova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Горбунова</surname><given-names>Екатерина Александровна</given-names></name><name xml:lang="zh"><surname>Gorbunova</surname><given-names>Ekaterina A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>opium-100@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1412-8066</contrib-id><contrib-id contrib-id-type="spin">4287-1951</contrib-id><name-alternatives><name xml:lang="en"><surname>Danilova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Данилова</surname><given-names>Анна Александровна</given-names></name><name xml:lang="zh"><surname>Danilova</surname><given-names>Anna A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>anya.danilova.02@list.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7757-6628</contrib-id><contrib-id contrib-id-type="spin">6144-1780</contrib-id><name-alternatives><name xml:lang="en"><surname>Medvedeva</surname><given-names>Nadezhda N.</given-names></name><name xml:lang="ru"><surname>Медведева</surname><given-names>Надежда Николаевна</given-names></name><name xml:lang="zh"><surname>Medvedeva</surname><given-names>Nadezhda N.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>medvenad@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7210-3020</contrib-id><contrib-id contrib-id-type="spin">3632-8415</contrib-id><name-alternatives><name xml:lang="en"><surname>Zukov</surname><given-names>Ruslan A.</given-names></name><name xml:lang="ru"><surname>Зуков</surname><given-names>Руслан Александрович</given-names></name><name xml:lang="zh"><surname>Zukov</surname><given-names>Ruslan A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>zukov_rus@mail.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sakhalin Regional Clinical Oncology Center</institution></aff><aff><institution xml:lang="ru">Сахалинский областной клинический онкологический диспансер</institution></aff><aff><institution xml:lang="zh">Sakhalin Regional Clinical Oncology Center</institution></aff><aff><institution xml:lang="kk"></institution></aff><aff><institution xml:lang="pt"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pacific State Medical University</institution></aff><aff><institution xml:lang="ru">Тихоокеанский государственный медицинский университет</institution></aff><aff><institution xml:lang="zh">Pacific State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Professor Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff><aff><institution xml:lang="ru">Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого</institution></aff><aff><institution xml:lang="zh">Professor Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">Красноярский краевой клинический онкологический диспансер им. А.И. Крыжановского</institution></aff><aff><institution xml:lang="zh">Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-05-09" publication-format="electronic"><day>09</day><month>05</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-06-23" publication-format="electronic"><day>23</day><month>06</month><year>2025</year></pub-date><volume>163</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>145</fpage><lpage>155</lpage><history><date date-type="received" iso-8601-date="2024-11-05"><day>05</day><month>11</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-02-14"><day>14</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-06-23"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://j-morphology.com/1026-3543/article/view/641577">https://j-morphology.com/1026-3543/article/view/641577</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Esophageal cancer is an oncological disease characterized by an extremely unfavorable course and prognosis. The high mortality rate associated with esophageal cancer underscores the importance of preventive screening programs in population and the need to expand the range of known risk factors for this disease. In this context, the study of physical development characteristics in patients with esophageal cancer is of particular interest.</p> <p><bold>AIM:</bold> To investigate somatometric and bioimpedance characteristics of physical development in patients with esophageal cancer.</p> <p><bold>METHODS: </bold>Anthropometric and bioimpedance measurements were conducted in 86 patients diagnosed with esophageal cancer. Body height and weight, shoulder and hip width, waist and hip circumference were measured. Body mass index and the sexual dimorphism index according to J.M. Tanner were calculated. Bioimpedance analysis was performed using the ABC01-036 hardware-software system (Medass, Russia). Body composition and phase angle were assessed. The phase angle of impedance reflects the intensity of metabolic processes in the body and is used as a prognostic indicator in oncological diseases. Statistical processing of the obtained data was performed using descriptive statistics methods. The Shapiro–Francia, Kolmogorov–Smirnov, Kruskal–Wallis, Fisher’s F-test, and Pearson’s chi-square test were used. Differences were considered statistically significant at <italic>p</italic> &lt; 0.05.</p> <p><bold>RESULTS:</bold> Normal body weight was noted in most women with squamous cell carcinoma of the esophagus and in men with esophageal adenocarcinoma. Among male patients with esophageal cancer, the mesomorphic body type predominated, with a shift toward gynecomorphy (<italic>p</italic> = 0.001). A mesomorphic somatotype prevailed among female patients (<italic>p</italic> = 0.001). No statistically significant differences in bioimpedance parameters were found among patients with esophageal cancer depending on somatotype. Decreased phase angle values relative to the reference range established for the Russian population were recorded with equal frequency in patients with esophageal cancer, regardless of disease stage, which allows this parameter to be considered a potential marker of poor prognosis.</p> <p><bold>CONCLUSION: </bold>Body weight deficiency is not typical for patients with esophageal adenocarcinoma. Overall, patients with esophageal cancer tend to exhibit a mesomorphic somatotype, with a shift toward gynecomorphy in men, as well as decreased phase angle values regardless of disease stage.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Рак пищевода — онкологическое заболевание, характеризующееся крайне неблагоприятным течением и прогнозом. Высокие показатели смертности от рака пищевода обуславливают необходимость проведения профилактических скрининговых мероприятий среди населения и расширения спектра известных факторов риска развития этого заболевания. В этой связи представляет интерес изучение особенностей физического развития пациентов с раком пищевода.</p> <p><bold>Цель</bold> — изучение соматометрических и биоимпедансометрических особенностей физического развития пациентов с раком пищевода.</p> <p><bold>Методы.</bold> Проведено антропометрическое и биоимпедансометрическое обследование 86 пациентов с диагнозом «рак пищевода». Определяли длину и массу тела, ширину плеч и таза, обхватные размеры талии и бёдер, а также рассчитывали индекс массы тела и индекс полового диморфизма по J.M. Tanner. Биоимпедансометрическое обследование проводили на аппаратно-программном комплексе АВС01-036 (ООО НТЦ «Медасс», Россия). Определяли компонентный состав тела и величину фазового угла. Фазовый угол импеданса отражает интенсивность обмена веществ в организме и используется в качестве прогностического показателя при онкологических заболеваниях. Проводили статистическую обработку полученных результатов с применением методов описательной статистики. Использовали критерии Шапиро–Франсиа, Колмогорова–Смирнова, Краскела–Уоллиса, а также F-критерий Фишера и Хи-квадрат Пирсона. Статистически значимыми считали различия при <italic>р</italic> &lt; 0,05.</p> <p><bold>Результаты.</bold> Нормальная масса тела отмечена у большинства женщин с плоскоклеточным раком пищевода и мужчин с аденокарциномой пищевода. Среди мужчин с диагнозом «рак пищевода» преобладали представители мезоморфного телосложения с инверсией пола в сторону гинекоморфии (<italic>р</italic> = 0,001). У женщин с раком пищевода преобладал мезоморфный морфотип телосложения (<italic>р</italic> = 0,001). Статистически значимых различий биоимпедансометрических показателей в зависимости от морфотипа телосложения у обследуемых пациентов с раком пищевода не выявлено. Пониженные значения величины фазового угла относительно референтных значений в общероссийской выборке одинаково часто регистрировались у пациентов с раком пищевода независимо от стадии заболевания, что позволяет рассматривать этот показатель как возможный маркер неблагоприятного прогноза заболевания.</p> <p><bold>Заключение.</bold> Установлено, что для пациентов с аденокарциномой пищевода не характерен дефицит массы тела. В целом у пациентов с раком пищевода преобладает мезоморфное телосложение с инверсией пола в сторону гинекоморфии у мужчин, а также снижена величина величины фазового угла вне зависимости от стадии заболевания.</p></trans-abstract><trans-abstract xml:lang="zh"><p>论证食管癌是一种临床过程极其凶险、预后较差的恶性肿瘤。其高死亡率凸显了在人群中开展预防性筛查、扩大相关危险因素研究的必要性。在此背景下，研究食管癌患者的体格发育特征具有重要意义。</p> <p><bold>目的：</bold>评估食管癌患者的体测学和生物电阻抗测量特征。</p> <p><bold>材料与方法。</bold>对86例食管癌确诊患者进行人体测量与生物电阻抗分析。测量项目包括身高、体重、肩宽、骨盆宽、腰围、臀围，并计算体重指数和J.M. Tanner性别二态性指数。生物电阻抗测量在АВС01-036型软硬件系统（“Medass”，俄罗斯）上进行。测量内容包括身体成分及相位角数值。相位角可反映机体代谢活性，常用作肿瘤患者的预后指标。对所得结果进行统计学处理，采用描述性统计方法。使用了Shapiro–Francia检验、Kolmogorov–Smirnov检验、Kruskal–Wallis检验、Fisher F检验及Pearson卡方检验。 以p &lt; 0.05为差异显著性标准。</p> <p><bold>结果。</bold>多数患食管鳞状细胞癌的女性患者和患食管腺癌的男性患者体重处于正常范围。在确诊为食管癌的男性患者中，以中等体型为主，并出现向女性型体型偏移的性别逆转趋势（p = 0.001）。在女性食管癌患者中，也以中等体型为主（p = 0.001）。在接受检查的食管癌患者中，依据体型分类，其生物电阻抗指标之间未发现统计学显著差异。相位角在食管癌患者中普遍低于俄罗斯参考值，且与肿瘤分期无关，提示其可能是判断该病不良预后的潜在标志物。</p> <p><bold>结论。</bold>食管腺癌患者通常不存在体重不足。总体上，食管癌患者以中体型为主，男性表现出体型女性化趋势，且其相位角普遍降低，与肿瘤分期无关。</p></trans-abstract><kwd-group xml:lang="en"><kwd>esophageal cancer</kwd><kwd>risk factors</kwd><kwd>anthropometry</kwd><kwd>bioimpedance analysis</kwd><kwd>body mass index</kwd><kwd>somatotype</kwd><kwd>phase angle</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак пищевода</kwd><kwd>факторы риска</kwd><kwd>антропометрия</kwd><kwd>биоимпедансометрия</kwd><kwd>индекс массы тела</kwd><kwd>соматотип</kwd><kwd>фазовый угол</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>食管癌</kwd><kwd>危险因素</kwd><kwd>人体测量</kwd><kwd>生物电阻抗分析</kwd><kwd>体重指数</kwd><kwd>体型类型</kwd><kwd>相位角</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834 EDN: FRJDQH</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lander S, Lander E, Gibson MK. Esophageal cancer: Overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep. 2023;25(11):275–279. doi: 10.1007/s11894-023-00899-0 EDN: ZCSNMO</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–7943. doi: 10.3748/wjg.v21.i26.7933</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Waters JK, Reznik SI. Update on management of squamous cell esophageal cancer. Curr Oncol Rep. 2022;24(3):375–385. doi: 10.1007/s11912-021-01153-4 EDN: SFHQSO</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422. doi: 10.6004/jnccn.2023.0019 EDN: WHZQFG</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18(6):432–443. doi: 10.1038/s41575-021-00419-3 EDN: NPDXUE</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010–1021. doi: 10.1007/s12328-020-01237-x EDN: ASXUOY</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gladilina IA, Tryakin AA, Zakhidova FO, et al. Esophageal cancer: epidemiology, risk factors and diagnostic methods. Journal of oncology: diagnostic radiology and radiotherapy. 2020;3(1):69–76. (In Russ.) doi: 10.37174/2587-7593-2020-3-1-69-76 EDN: DUVSPG</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zyuzyukina AV, Gasymly DDK, Komissarova VA, et al. Anthropometric and topometric characterization of patients with breast cancer. Russian Journal of Oncology. 2021;26(3):77–84. (In Russ.) doi: 10.17816/onco107114 EDN: ISNXQQ</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Khusnutdinov RM, Sitdikov AM, Fatkullov IR, et al. Comparative analysis of the functional state of the body of athletes and non-athletes according to anthropometry, morphology and IPC. Scientific notes of the P.F. Lesgaft University. 2023;12(226):208–213. (In Russ.) EDN: WQVFSM</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Orlov VA, Razumov AN, Strizhakova OV, Fudin NA. Human health - an “activity-based” approach and quantitative measurement. Journal of new medical technologies, eEdition. 2022;16(5):64–70. (In Russ.) doi: 10.24412/2075-4094-2022-5-2-2 EDN: DEGMAA</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Sakibaev KSh, Nikityuk DB, Nikolaev DV, et al. Experience in the use of bioimpedance measurement to assess the composition of the human body. Bulletin of Medicine and Education. 2021;(2):137–146. (In Russ.) EDN: FIXXIU</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kostyuchenko LN, Kruglov AD, Kostyuchenko MV, Lychkova AE. Method of bioimpedancemetria for assessing metabolism in colorectal cancer and pancreatic cancer. Medical Alphabet. 2019;4(38):54–58. (In Russ.) doi: 10.33667/2078-5631-2019-4-38(413)-54-58 EDN: UVYLFM</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kamalova AA, Safina ER, Gaifutdinova AR. Body composition in children with inflammatory bowel diseases. Practical medicine. 2022;20(1):67–73. (In Russ.) doi: 10.32000/2072-1757-2022-1-67-73 EDN: WYPJES</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zharikov YuO, Kovaleva ON, Maslennikov RV, Gadzhiakhmedova AN. Nutritional status of patients with cirrhosis of the liver. Chronos. 2022;7(11(73)):30–32. (In Russ.) doi: 10.52013/2658-7556-73-11-8 EDN: SDTULQ</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rudnev SG, Soboleva NP, Sterlikov SA. Bioimpedance study of the body composition in the Russian population. Moscow: Federal Research Institute for Health Care Organization and Information; 2014. (In Russ.) ISBN: 5-94116-018-6 EDN: TDSYFP</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hui D, Moore J, Park M, et al. Phase angle and the diagnosis of impending death in patients with advanced cancer: Preliminary findings. Oncologist. 2019;24(6):e365–e373. doi: 10.1634/theoncologist.2018-0288</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Miura T, Matsumoto Y, Kawaguchi T, et al. Low phase angle is correlated with worse general condition in patients with advanced cancer. Nutr Cancer. 2019;71(1):83–88. doi: 10.1080/01635581.2018.1557216</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Koyanagi YN, Matsuo K, Ito H, et al. Body mass index and esophageal and gastric cancer: A pooled analysis of 10 population-based cohort studies in Japan. Cancer Sci. 2023;114(7):2961–2972. doi: 10.1111/cas.15805 EDN: EYZUSN</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Loehrer EA, Giovannucci EL, Betensky RA, et al. Prediagnostic adult body mass index change and esophageal adenocarcinoma survival. Cancer Med. 2020;9(10):3613–3622. doi: 10.1002/cam4.3015 EDN: ZHZJBK</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Li S, Xie K, Xiao X, et al. Correlation between sarcopenia and esophageal cancer: a narrative review. World J Surg Oncol. 2024;22(1):27. doi: 10.1186/s12957-024-03304-w EDN: DEIGGP</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Jogiat UM, Bédard ELR, Sasewich H, et al. Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(6):2630–2636. doi: 10.1002/jcsm.13082 EDN: GAERDW</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Boshier PR, Heneghan R, Markar SR, et al. Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31(8). doi: 10.1093/dote/doy047</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tanner JM. Childhood epidemiology. Physical development. Br Med Bull. 1986;42(2):131–138. doi: 10.1093/oxfordjournals.bmb.a072110 EDN: ILSADT</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sindeyeva LV, Rudnev SG. Characteristic of the age and sex-reated variability of the Heath-Carter somatotype in adults and possibility of its bioimpedance assessment (as exemplified by Russian population of Eastern Siberia). Morphology. 2017;151(1):77–87 (In Russ.) EDN: YKUYXN</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>van der Schaaf MK, Tilanus HW, van Lanschot JJ, et al. The influence of preoperative weight loss on the postoperative course after esophageal cancer resection. J Thorac Cardiovasc Surg. 2014;147(1):490–495. doi: 10.1016/j.jtcvs.2013.07.072</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Gu WS, Fang WZ, Liu CY, Pan KY, Ding R, Li XH, Duan CH. Prognostic significance of combined pretreatment body mass index (BMI) and BMI loss in patients with esophageal cancer. Cancer Manag Res. 2019;11:3029–3041. doi: 10.2147/CMAR.S197820</mixed-citation></ref></ref-list></back></article>
